ucsf-924

UCSF924 is a potent and specific agonist of dopamine D4 receptor (DRD4) partial (EC50: 4.2 nM, Ki: 3 nM).

Azalanstat HCl is an anti-obesity drug acting as a lanosterol 14α-demethylase inhibitor. Azalanstat HCl has been shown to inhibit cholesterol synthesis in HepG2 cells, human fibroblasts, hamster hepatocytes and hamster liver, by inhibiting the cytochrome P450 enzyme lanosterol 14 alpha-demethylase. When administered orally to hamsters fed regular chow, RS-21607 (50 mg kg day) lowered serum cholesterol in a dose-dependent manner (ED50 = 62 mg kg) in a period of 1 week. It preferentially lowered low density lipoprotein (LDL) cholesterol and apo B relative to high density lipoprotein (HDL) cholesterol and apo A-1.

UCSF924NC is the recommended negative control compound for the high-affinity dopamine D4 receptor (DRD4) partial agonist UCSF924. UCSF924NC exhibits a 1 2500-fold reduced D4 affinity when compared with that of UCSF924.